Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05406622 · ClinicalTrials.gov registry record · NA
MOTIV BTK Randomized Controlled Trial
A NA study of Critical Limb Ischemia, sponsored by REVA Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 292
- Enrollment target
- 4
- Study locations
NCT05406622 is a NA study of Critical Limb Ischemia that is actively recruiting participants, run by REVA Medical. The registered enrollment target is 292 participants, above the 75-participant average among 18 other Critical Limb Ischemia trials with a reported enrollment target (289% higher). The trial reports 4 study locations across 3 states.
The verdict
NCT05406622, a NA study of Critical Limb Ischemia, is actively recruiting participants, sponsored by REVA Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 292 participants
- Enrollment target
- 4
- Study locations
Study Summary
Pre-market clinical evaluation of the MOTIV Sirolimus-Eluting Bioresorbable Scaffold for the planned treatment of infrapopliteal lesions.
Conditions Studied
Interventions
- DEVICE MOTIV Sirolimus-Eluting Bioresorbable Scaffold
- DEVICE Percutaneous Transluminal Angioplasty (PTA) Device
Study Locations (4)
Iowa
- UnityPoint Health Trinity Bettendorf Hospital - Bettendorf
- Cardiovascular Medicine PC - Davenport
California
- Adventist Health - St. Helena
Other
- University Leipzig - Leipzig
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2022-06-10 |
| Est. Completion | 2029-03-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05406622
The ClinicalTrials.gov registry entry for NCT05406622 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 75-participant average among 18 other Critical Limb Ischemia trials with a reported enrollment target (289% higher). The listed sponsor is REVA Medical, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Critical Limb Ischemia appearing as the primary indexed condition, and to 2 interventions - of which MOTIV Sirolimus-Eluting Bioresorbable Scaffold is the first listed.
NCT05406622 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Iowa, California, Other.
Frequently Asked Questions
What is clinical trial NCT05406622 about?
NCT05406622 is a clinical study titled "MOTIV BTK Randomized Controlled Trial". Pre-market clinical evaluation of the MOTIV Sirolimus-Eluting Bioresorbable Scaffold for the planned treatment of infrapopliteal lesions.
What is the current status of trial NCT05406622?
This trial is currently recruiting. It is a NA study. The enrollment target is 292 participants. The study started on 2022-06-10. Estimated completion is 2029-03-31.
What conditions does trial NCT05406622 study?
This clinical trial studies the following conditions: Critical Limb Ischemia.
What interventions are being tested in trial NCT05406622?
The interventions under investigation include: MOTIV Sirolimus-Eluting Bioresorbable Scaffold (DEVICE), Percutaneous Transluminal Angioplasty (PTA) Device (DEVICE).
Who is sponsoring clinical trial NCT05406622?
This trial is sponsored by REVA Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05406622 being conducted?
This trial has 4 study locations across California, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Critical Limb Ischemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
RECRUITING · NA
-
Serrantor OCT Study
RECRUITING · NA
-
Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries
COMPLETED · NA
-
A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)
COMPLETED · NA
-
BOLD MRI as a Surrogate of Improved Muscle Oxygenation Following Endovascular Therapy for the Treatment of CLI
COMPLETED · NA
-
PROMISE I Early Feasibility Trial of the LimFlow Stent Graft System
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.